Francesco Giorgino | Metabolic Therapies and Longevity: Beyond Disease Management | MLS26

*Dual GLP-1R/GIP-R Agonists* What happens when one therapy targets two of the body's key metabolic signalling pathways at once? In this session from *Metabolic Therapies and Longevity: Beyond Disease Management* at the *Milan Longevity Summit 2026*, *Professor Francesco Giorgino* explores the science behind dual GLP-1/GIP receptor agonists and their emerging role in metabolic medicine. By acting simultaneously on two incretin pathways, these therapies are producing significant effects on glucose regulation, appetite, body weight, and metabolic function. Their development represents a new generation of treatments designed to influence multiple interconnected mechanisms rather than a single disease pathway. Professor Giorgino examines how dual agonists work, what clinical research is revealing about their potential, and how these therapies could reshape the management of obesity, diabetes, and metabolic risk over the lifespan. Professor Francesco Giorgino is Full Professor of Endocrinology at the *University of Bari Aldo Moro* and an internationally recognised expert in diabetes, insulin signalling, obesity, and metabolic disease. His research bridges molecular endocrinology and clinical medicine to improve understanding and treatment of metabolic disorders. The Milan Longevity Summit brings together global leaders across science, medicine, policy, business, technology and society to rethink the future of health through a *One Health* perspective—recognising that the wellbeing of people, planet and economies is deeply interconnected. *Learn more about the Milan Longevity Summit:* https://www.milanlongevitysummit.org/it/speakers26/francesco-giorgino #MilanLongevitySummit #Longevity #OneHealth #FrancescoGiorgino #GLP1 #GIP #MetabolicHealth #Obesity #Diabetes #Healthspan